Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.